drugset / Trial / NCT06100627
A Pharmacodynamic Effect Study of AP301 in Healthy Volunteers
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a randomized, open-label, parallel-group, phase 1 study to evaluate the PD effect of AP301 capsule in healthy volunteers. The study is planned to have 4 treatment arms: Arm 1: 2.10 g/day; arm 2: 4.20 g/day; arm 3: 6.30 g/day; arm 4: 8.40 g/day.
Timeline
- Start
- 2024-01-11
- Primary completion
- 2024-02-08
- Completion
- 2024-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AP301 | Unknown | 2.1 g | Oral |
| Subject | AP301 | Unknown | 4.2 g | Oral |
| Subject | AP301 | Unknown | 6.3 g | Oral |
| Subject | AP301 | Unknown | 8.4 g | Oral |
Indications
No indication recorded.